Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission

Vydra, Jan; Šálek, Cyril; Schwarz, Jiřı́; Зак, Павел; Novák, Jan; Petečuková, Veronika; Pecherková, Pavla; Mayer, Jiřı́; Cetkovský, Petr; Ráčil, Zdeněk

doi:10.1016/j.clml.2017.11.011

Cited by 2 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proposed molecular risk groups also differed in their benefit from alloHSCT, which might be advantageously utilized in treatment decision strategies. In a previous study, we were not able to clearly confirm the benefit of alloHSCT in the first complete remission in the non-selected group of intermediate cytogenetic risk patients without these NGS mutation profiles (Vydra et al, 2018). We believe that this or a similar approach could be easily adopted into routine clinical practice.…”

Section: Discussionmentioning

confidence: 68%

Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary In this multi‐centre study, we analysed the prognostic impact of mutations in 19 genes associated with myeloid malignancies in 258 newly diagnosed acute myeloid leukaemia patients (aged 19–70 years) undergoing intensive therapy. We identified five patient groups with different prognostic risks and different benefits from allogeneic hematopoietic stem cell transplantation (alloHSCT) within the intermediate cytogenetic risk group patients (n = 184). The most adverse prognosis was observed in patients with DNMT3A and FLT3‐ITD co‐mutation, whose survival could be significantly improved with alloHSCT. In contrast, the most favourable prognosis without any further benefit from alloHSCT was identified in patients with mutations in NPM1 or CEBPA, after exclusion of the unfavourable prognostic groups defined by mutations in DNMT3A, RUNX1 or genes from chromatin/spliceosome group. An additional analysis of 113 diagnosis‐remission paired samples revealed that persistence of non‐DNMT3A mutations (above 2% VAF) represented a further negative prognostic factor. The proposed model offers a possible molecular stratification and treatment guidance for intermediate cytogenetic risk group patients.

show abstract

Section: Discussionmentioning

confidence: 68%